DJIA 17,804.80 26.65 0.15%
NASDAQ 4,765.38 16.98 0.36%
S&P 500 2,070.65 9.42 0.46%
market minute promo

VIVUS, Inc. (NASDAQ: VVUS)



company name or ticker

Emergent BioSolutions Revamps Business to Drive Earnings - Analyst Blog

3 Biotech Stocks Near 52-Week Lows Worth Buying

These may be cheap biotech stocks, but they may not be cheap for long according to the three analysts we asked.

Halozyme's PEGPH20 Receives FDA Orphan Drug Designation - Analyst Blog

Halozyme's PEGPH20 Receives FDA Orphan Drug Designation - Analyst Blog

Regeneron's Eye Drug Eylea Wins Another FDA Approval - Analyst Blog

Orexigen On A Tear - In The Wrong Direction

Is VIVUS Inc. a Short Sell?

Shares of VIVUS Inc. have crashed by over 60% in the past year. Is the stock still a good short sell?

Premature Combination Use Of Belviq And Phentermine Is A Risk

Belviq Sales Benefit From Advertising - Up 2.8%

VIVUS and Auxilium Announce Stendra Label Expansion - Analyst Blog

3 Biotechs Investors Should Watch

The healthcare version of Where the Money Is.
See More Articles...